VANDA PHARMACEUTICALS ($VNDA) posted quarterly earnings results for Q1 2026 on Wednesday, May 6th. The company reported earnings of -$0.82 per share, missing estimates of -$0.70 by $0.12. The company also reported revenue of $51,720,000, missing estimates of $56,077,560 by $-4,357,560.
Stock price change since market close: -2.57%
You can see Quiver Quantitative's $VNDA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
VANDA PHARMACEUTICALS Insider Trading Activity
VANDA PHARMACEUTICALS insiders have traded $VNDA stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $VNDA stock by insiders over the last 6 months:
- MIHAEL HRISTOS POLYMEROPOULOS (President and CEO) sold 156,235 shares for an estimated $1,276,971
- KEVIN PATRICK MORAN (SVP, CFO & Treasurer) sold 42,442 shares for an estimated $350,821
- TIMOTHY WILLIAMS (SVP & General Counsel) sold 42,434 shares for an estimated $350,755
- GUNTHER BIRZNIEKS (SVP, Business Development) sold 42,431 shares for an estimated $350,730
- JOAKIM WIJKSTROM (SVP, Chief Marketing Officer) sold 30,800 shares for an estimated $254,589
- TAGE HONORE sold 30,000 shares for an estimated $240,899
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
VANDA PHARMACEUTICALS Hedge Fund Activity
We have seen 68 institutional investors add shares of VANDA PHARMACEUTICALS stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC removed 2,353,307 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $20,756,167
- MILLENNIUM MANAGEMENT LLC removed 1,571,823 shares (-48.4%) from their portfolio in Q4 2025, for an estimated $13,863,478
- BLACKROCK, INC. removed 1,144,770 shares (-12.8%) from their portfolio in Q4 2025, for an estimated $10,096,871
- AIGH CAPITAL MANAGEMENT LLC added 751,569 shares (+37.6%) to their portfolio in Q1 2026, for an estimated $5,193,341
- JACOBS LEVY EQUITY MANAGEMENT, INC added 599,818 shares (+552.3%) to their portfolio in Q4 2025, for an estimated $5,290,394
- MARSHALL WACE, LLP removed 581,247 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,126,598
- PRUDENTIAL FINANCIAL INC removed 449,403 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,963,734
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
VANDA PHARMACEUTICALS Government Contracts
We have seen $171,234 of award payments to $VNDA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PHARM - HETLIOZ: $171,234
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
VANDA PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $VNDA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/23/2026
To track analyst ratings and price targets for VANDA PHARMACEUTICALS, check out Quiver Quantitative's $VNDA forecast page.
VANDA PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $VNDA recently. We have seen 4 analysts offer price targets for $VNDA in the last 6 months, with a median target of $16.0.
Here are some recent targets:
- Les Sulewski from Truist Securities set a target price of $18.0 on 03/05/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $24.0 on 02/23/2026
- Chris Howerton from Jefferies set a target price of $7.5 on 12/31/2025
- Madison El-Saadi from B. Riley Securities set a target price of $14.0 on 12/31/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
